Plaque Psoriasis Epidemiology Forecast 2025-2034

The plaque psoriasis epidemiological forecast indicates that its prevalence is expected to rise due to factors such as an aging population, increasing environmental pollutants, and lifestyle changes like diet, stress, and sedentary behavior. Plaque psoriasis, also known as psoriasis vulgaris, is the most common type, affecting about 8 in 10 people with psoriasis. According to the World Psoriasis Day Consortium, approximately 125 million people worldwide are affected by psoriasis, including plaque psoriasis.

Plaque Psoriasis Epidemiology Forecast Report Coverage

The “Plaque Psoriasis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of plaque psoriasis. It projects the future incidence and prevalence rates of plaque psoriasis cases across various populations. The study covers age and type as major determinants of the plaque psoriasis population. The report highlights patterns in the prevalence of plaque psoriasis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on plaque psoriasis epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Plaque Psoriasis Understanding: Disease Overview

Plaque psoriasis is the most common type of psoriasis, characterized by the rapid growth of skin cells. In this condition, the formation of thick, red, scaly patches occurs on the skin of the patient. The patches, or plaques, primarily appear on the scalp, elbows, knees, and lower back, though they can develop anywhere on the body.

Plaque psoriasis occurs when the immune system attacks healthy skin cells, triggering an accelerated skin cell turnover. A family history of psoriasis or other autoimmune conditions increases the risk of developing the condition. Environmental triggers include infections, stress, skin injuries, certain medications, and cold weather, among others.

Plaque Psoriasis Epidemiology Perspective

The plaque psoriasis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for plaque psoriasis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The plaque psoriasis detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Plaque psoriasis, also known as psoriasis vulgaris, is the most common type, affecting about 8 in 10 people with psoriasis, as reported by WebMD.
• According to the World Psoriasis Day Consortium, approximately 125 million people worldwide, or 2 to 3 percent of the total population, have psoriasis, including plaque psoriasis.
• It is observed that plaque psoriasis appears in two age groups: the first peak is between ages 16 to 22, and the second between ages 57 to 60. Women tend to develop plaque psoriasis earlier than men, and individuals with a family history of psoriasis often experience an earlier onset.
• Research shows a significant risk of developing psoriatic arthritis in patients with plaque psoriasis, with estimates ranging from 7% to 48%.
• Epidemiological studies show a higher prevalence of psoriasis, including plaque psoriasis, in Western European and Scandinavian populations, where 1.5% to 3% of the population is affected by the condition.

Country-wise Plaque Psoriasis Epidemiology Segment

The plaque psoriasis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of plaque psoriasis varies significantly between countries due to differences in factors such as genetic predisposition, environmental exposures, lifestyle habits, healthcare access, and diagnostic practices, among others. Studies show that plaque psoriasis occurs worldwide, with its prevalence varying based on race, geography, and environmental factors, such as sun exposure. In the United States, approximately 1% to 2% of the population is affected by plaque psoriasis.

Plaque Psoriasis: Treatment Overview

The treatment approach for plaque psoriasis is focused on managing symptoms and reducing flare-ups. Topical plaque psoriasis therapeutics, including corticosteroids to reduce inflammation, vitamin D analogs to slow skin cell growth, and moisturizers to relieve dryness and scaling, are commonly used by patients.

In severe plaque psoriasis cases, phototherapy and systemic treatments may be recommended. Oral medications such as methotrexate or cyclosporine, which suppress the immune system, and biologic therapies that target specific immune responses, are some of the popular systemic treatments.

Key Questions Answered

• What are the key findings of plaque psoriasis epidemiology in the 8 major markets?
• What will be the total number of patients with plaque psoriasis across the 8 major markets during the forecast period?
• What was the country-wise plaque psoriasis epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of plaque psoriasis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of plaque psoriasis during the forecast period of 2025-2034?
• What are the currently available treatments in the plaque psoriasis market?
• What are the disease risks, signs, symptoms, and unmet needs of plaque psoriasis?

Scope of the Plaque Psoriasis Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of plaque psoriasis based on several factors.
• The Plaque Psoriasis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The plaque psoriasis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.